Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark

Søg

Menu

Close

Log indLog udLægemidlerTerapiområderPfizerConnectPfizerConnectArrangementerMaterialerEfteruddannelse

Information om bivirkningsindberetning findes nederst på denne side

AboutAlopecia AreataLITFULO Mechanism of ActionSALT EvaluationEfficacyALLEGRO-2b/3 Study OverviewScalp Hair ResponsePatient-reported OutcomesEyebrow & Eyelash ResponseBefore & After ImagesSafetyALLEGRO-2b/3 Adverse ReactionsAdditional Safety ConsiderationsGetting StartedDosingScreening & MonitoringSetting Patient ExpectationsResourcesMaterialsVideos
Additional Safety Considerations[1] 
Scroll left to view table
Contraindications
  • Hypersensitivity to LITFULO or any of its excipients
  • Active serious infections, including TB
  • Severe hepatic impairment
  • Pregnancy and breastfeeding
Not recommended in
  • Patients with end-stage renal disease or transplant
  • Women of child-bearing potential who are not using contraception
Do not initiate in
  • Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
  • ALC <0.5 x 103/mm3
  • Platelet count <100 x 103/mm3
Risks and benefits should be considered prior to initiating in patients who have
  • Chronic or recurrent infections and/or underlying conditions that may predispose them to infection
  • History of serious or opportunistic infection
  • Been exposed to TB; patients residing within or who have travelled to areas of endemic TB or mycoses
  • A known malignancy other than a successfully treated NMSC or cervical cancer
  • Patients with known risk factors for thromboembolism
Use with caution in
  • Elderly patients and patients with diabetes who may have increased risk for infections

Table made by Pfizer based on data in ref. 1

 Get appropriate patients started on LITFULO today Dosing & monitoring LoadingALC=absolute lymphocyte count; NMSC=nonmelanoma skin cancer; TB=tuberculosis.Reference:1. LITFULO (ritlecitinib) SmPC.Safety Get appropriate patients started on LITFULO today Getting started Loading
 Indication Litfulo® (ritlecitinib):
 Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.[Litfulo SmPC] 
 Litfulo pligttekst

Bivirkninger skal indberettes. Hvis du vil rapportere en bivirkning, kan du kontakte Pfizer på e-mail: [email protected]

 

PfizerPro kontoPfizerPro konto

Få adgang til information, materialer, efteruddannelse samt modtag kommunikation om Pfizers lægemidler og vacciner.

Log indRegisterMin profilLog ud

Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark.

Denne hjemmeside er udarbejdet til dig af Pfizer Danmark.

 

© Pfizer 2023. Alle rettigheder til denne hjemmeside forbeholdes Pfizer ApS.

12 August 2025 * PP-LGF-DNK-0008
Du forlader nu Pfizer
Du forlader nu et Pfizer-drevet website. Links til alle eksterne websites leveres som en ressource til vores besøgende. Pfizer påtager sig intet ansvar for indholdet af websites, der ikke ejes og drives af Pfizer.